Home › Research › Risk factors
Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows
Praticò D.. Annals of the New York Academy of Sciences, 2008-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the most common form of neurodegenerative disease associated with dementia in the elderly. Although the initiating events are still unknown, it is clear that AD, at least in its sporadic form, results from the combination of genetic risk factors with different epigenetic events. Among them, a growing body of evidence suggests that an imbalance between free radical formation and destruction is involved in AD pathogenesis. This concept originally derived from the free radical hypothesis of aging, which states that the age-related accumulation of free radicals results in damaged cell components. The fact that age is a key risk factor in AD provides support for this hypothesis. There is a long list of surrogate markers, which includes lipid, DNA, and protein oxidation, of oxidant stress-mediated injury that have been reported as elevated in the AD brain. Moreover, epidemiologic studies show that dietary intake of natural or synthetic products with a putative antioxidant effect, such as (but not only) vitamin E, reduces the risk of AD. On the other hand, antioxidative intervention studies in animal models of AD-like amyloidosis show a significant reduction in amyloid beta deposition and behavioral improvements. However, a randomized clinical trial of vitamin E supplementation in AD patients shows only a marginal positive effect. Another study reports no effect of vitamin E on the rate of progression of AD in subjects with mild cognitive impairment. This article will review both promises and caveats of the available data and propose future directions to be taken for addressing them.
What this study adds
Evidence grade: High
This is a narrative review. This review describes evidence of oxidative stress in Alzheimer's disease brains and mixed results from antioxidant studies, including only a marginal effect of vitamin E in one trial and no effect in another. It does not show that antioxidant therapy treats or prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Praticò, D. (2008). Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1427.010
Vancouver
Praticò D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Annals of the New York Academy of Sciences. 2008. doi:10.1196/annals.1427.010. PMID: 19076432.
BibTeX
@article{pratico2008-19076432,
author = {Praticò, D.},
title = {{Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows}},
journal = {Annals of the New York Academy of Sciences},
year = {2008},
doi = {10.1196/annals.1427.010},
pmid = {19076432},
url = {https://doi.org/10.1196/annals.1427.010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Alzheimer's disease (AD) is the most common form of neurodegenerative disease associated with dementia in the elderly.
- Although the initiating events are still unknown, it is clear that AD, at least in its sporadic form, results from the combination of genetic risk factors with different epigenetic events.
- Among them, a growing body of evidence suggests that an imbalance between free radical formation and destruction is involved in AD pathogenesis.
- This concept originally derived from the free radical hypothesis of aging, which states that the age-related accumulation of free radicals results in damaged cell components.
- On the other hand, antioxidative intervention studies in animal models of AD-like amyloidosis show a significant reduction in amyloid beta deposition and behavioral improvements.
Why it matters
This review describes evidence of oxidative stress in Alzheimer's disease brains and mixed results from antioxidant studies, including only a marginal effect of vitamin E in one trial and no effect in another. It does not show that antioxidant therapy treats or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthHigh
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Annals of the New York Academy of Sciences) |
| Journal's citation record | 3 / 4 | Annals of the New York Academy of Sciences: journal h-index 399 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 313 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.7 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 4 / 6 | Cited 17.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Domenico Praticò: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Temple University: institution h-index 742 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19076432) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Risk factors from nearby years
Also in Risk factors
395 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.